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Sites involved in antibody-mediated neutralization of feline immunodeficiency virus were mapped by recip-
rocal exchange of envelope fragments or amino acids between molecular clones of feline immunodeficiency
virus with different susceptibilities to neutralization by a polyclonal cat serum. Combinations of mutations
within HV-4 or within HV-4 and HV-5 changed the susceptibility of the viruses to neutralizing antibody.
Feline immunodeficiency virus (FIV) is a lentivirus that
causes a severe impairment of immune function in experimen-
tally and naturally infected cats, which eventually results in the
development of a syndrome quite similar to AIDS in humans
(1, 4, 8, 11, 12, 14, 18, 19, 22, 25, 28). For both human immu-
nodeficiency virus type 1 and FIV it has been shown that single
amino acid substitution mutations in the envelope glycopro-
tein, within or outside the presently identified VN epitopes,
may confer resistance to virus-neutralizing (VN) monoclonal
or polyclonal antibody (13, 16, 20, 23, 27). It has also been
postulated that glycosylation may play an important role in the
proper expression or masking of VN epitopes (2, 5, 6, 9, 10).
We have recently described two molecular clones of FIV
(FIV19k1 and FIV19k32), simultaneously derived from a nat-
urally infected cat (21). These clones differed in their suscep-
tibilities to virus neutralization in feline thymocytes by serum
S1422, obtained from a specific-pathogen-free cat, 22 weeks
after infection with FIV19k1 (23). The surface glycoproteins
(SU) of the two molecular clones were shown to differ in only
five amino acids (21). We have demonstrated that a single
substitution mutation at amino acid position 560 (HV-5) or at
position 483 of FIV19k1 conferred resistance to virus neutral-
ization by S1422 (20, 23). In the present study we have further
evaluated the involvement of different sites of the SU protein
in antibody-mediated neutralization by reciprocal exchange of
FIV19k1 and FIV19k32 envelope gene fragments and by site-
directed mutagenesis. This included a highly conserved poten-
tial N-linked glycosylation site at amino acid position 481 (24).
Combinations of point mutations were made in the SU pro-
tein of FIV19k32, on basis of the FIV19k1 sequence, in order
to obtain a virus neutralization-sensitive mutant of FIV19k32.
To this end, site-directed mutagenesis and gene fragment ex-
change were carried out as previously described (20, 23). Rep-
lication competence of the molecular and chimeric clones was
confirmed by showing that the production of FIV antigen in
independent duplicate thymocyte cultures was of the same
order of magnitude as FIV antigen production of cultures
infected with FIV19k1 or FIV19k32 (less than 100.5 times dif-
ference), under previously described conditions (20, 23). Two
virus neutralization-sensitive chimeric viruses, FIV19k32mutA
(Asp-454 to Asn and Ser-483 to Leu) and FIV19k32mutB (Ser-
483 to Leu and HV-5 region of 19k1), were thus constructed.
The VN indices of S1422 for the respective viruses were mea-
sured as previously described (20, 23) and were 14 and 25 on
day 8 and 5 and 9 on day 12 (Fig. 1A). FIV19k1 and FIV19k32
and the chimeric viruses FIV19k1mutA, FIV19k1mutB,
FIV19k32mutC, FIV19k32mutD, and FIV19k32mutE, which had
been generated previously and contained only one or two point
mutations compared with their parent viruses, were also tested
in the same experiment. Essentially the same results were
obtained as in previous studies (20, 23) (Fig. 1A). These data
show that a point mutation reciprocal to the Leu-to-Ser mu-
tation at amino acid position 483, which has been shown to
render FIV19k1 insensitive to neutralization by S1422 (20),
renders FIV19k32 sensitive to this neutralization only if at
least an additional mutation at amino acid position 454 is
created or additional exchange of HV-5 is achieved (Fig. 1A).
The Leu-to-Ser substitution at amino acid position 483 of
FIV19k1 introduces a potential N-linked glycosylation site at
position 481. To investigate the role of this potential N-linked
glycosylation in the mechanism of neutralization and escape,
12 chimeric clones were constructed by site-directed mutagen-
esis (Fig. 1B). To test whether the Ser at amino acid position
483 itself was important, we substituted in the SU protein
of FIV19k1, FIV19k32, FIV19k32mutA, and FIV19k32mutB
the Leu by a Thr at this position. This resulted in chimeric
clones FIV19k1mutD, FIV19k32mutF, FIV19k32mutA1, and
FIV19k32mutB1, respectively, with a potential N-linked glyco-
sylation site in the absence of a Ser at this position. Replica-
tion of FIV19k1mutD in the presence of S1422 proved to be
inhibited (Fig. 1B). Thus, independently from the poten-
tial N-linked glycosylation site, the actual amino acid pres-
ent at amino acid position 483 does influence the S1422
virus neutralization phenotype of the virus. The VN pheno-
types of chimeric clones FIV19k32mutF, FIV19k32mutA1, and
FIV19k32mutB1 were similar to that of the parent virus
FIV19k32: none of these chimeric viruses were neutralized by
S1422 (Fig. 1B).
To disrupt the potential N-linked glycosylation site at posi-
tion 481 in the SU protein of FIV19k1mutB, FIV19k32,
FIV19k32mutC, and FIV19k32mutE, the Asn at amino acid po-
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FIG. 1. Schematic representation of parts of the HV-4 and HV-5 regions of FIV19k1 and FIV19k32 and chimeric viruses constructed by exchange of single or
multiple amino acids in the HV-4 and HV-5 regions of FIV19k1 and FIV19k32 (A) and by altering the potential N-linked glycosylation site at amino acid position 481
(B). S1422 VN indices measured on days 8 and 12 against the respective viruses are also shown (p, data from reference 20). The envelope glycoprotein is diagrammed
at the top. The hypervariable regions are numbered 1 through 5. Restriction enzyme cleavage sites: K, KpnI; M, MstII; N, NsiI. Open and shaded bars, sequences of
FIV19k1 and FIV19k32, respectively. The amino acid sequence of clone FIV19k1 is shown. The individual mutated (and relevant nonmutated) amino acids are
indicated, with shading and lack of shading indicating the virus of origin (see above). Amino acids which alter the potential N-linked glycosylation site and which are
not present in FIV19k1 or FIV19k32 are highlighted in black.
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sition 481 was substituted by a Gln, another uncharged polar
amino acid. This resulted in chimeric viruses FIV19k1mutB1,
FIV19k32mutG, FIV19k32mutC1, and FIV19k32mutE1, respec-
tively. None of these viruses were neutralized by S1422 (Fig.
1B).
Finally, to control for a potential virus neutralization site
disruption by the presence of a Gln at amino acid position 481,
the Asn at amino acid position 481 of clones FIV19k1,
FIV19k32mutD, FIV19k32mutA, and FIV19k32mutB was also
substituted by a Gln, resulting in chimeric clones FIV19k1mutE,
FIV19k32mutD1, FIV19k32mutA2, and FIV19k32mutB2, respec-
tively. With the exception of FIV19k32mutA2, the introduction
of Gln at this position did not change the S1422 virus neutral-
ization phenotype of these viruses significantly. The replication
of FIV19k32mutA2 proved to be slightly inhibited. The neutral-
ization of the parent virus of FIV19k32mutB2 was not signifi-
cantly different from neutralization of the mutated virus (Fig.
1B).
In the experiments presented in this article we have used a
thymocyte virus neutralization assay, since viral progeny of
molecular clones 19k1 and 19k32 replicates only in feline T
cells, a primary target for FIV infection. It has been shown that
sera from FIV-infected cats that neutralize FIV infection of
CrFK cells with CrFK-adapted FIV strains fail to neutralize
FIV infection of thymocytes, peripheral blood mononuclear
cells, or a T-lymphoid cell line (3, 23, 26). The FIV-neutraliz-
ing activity demonstrated in the CrFK virus neutralization as-
say proved to be mediated predominantly by antibodies di-
rected to an immunodominant epitope in HV-3 (7, 15). This
suggests that HV-3-specific antibodies largely fail to neutralize
FIV in the thymocyte virus neutralization assay and that the
HV-3 domain, if at all, is only indirectly involved in the mech-
anisms of virus neutralization in feline thymocytes.
Be it as it may, in the present article we have shown that both
the HV-4 and the HV-5 domains of two closely related FIV
clones are directly involved in FIV neutralization in feline
thymocytes. With bacterially expressed envelope fragments of
FIV it was shown that the HV-4 region contains a highly
type-specific antigenic site (7, 17). However, in Pepscan anal-
ysis of both regions using 12-mers we could not obtain evidence
for true linear epitopes in these regions (20, 23) (unpublished
data), indicating that the epitopes involved are to a certain
extent conformation dependent. It is interesting to note that
the location of the regions involved in FIV neutralization iden-
tified here is reminiscent of the CD4 binding site of human
immunodeficiency virus type 1, which is a discontinuous site
with contributions mostly from the carboxy-terminal half of the
SU protein. Antibodies to the CD4 binding site have VN
activity, just like the antibodies present in serum S1422. On the
basis of these similarities it may be hypothesized that the HV-4
and HV-5 regions of the SU protein contribute to the defini-
tion of the binding site for the cellular receptor of FIV.
Together with previously reported results (20, 23) the data
presented show that mutations in the HV-4 and HV-5 regions
influence the susceptibility of FIV to antibody-mediated neu-
tralization.
This work was supported by a grant from the Dutch Advisory Coun-
cil on Health Research (RGO grant 88-90/89028).
We thank Conny Kruyssen for assistance in preparing the manu-
script.
REFERENCES
1. Ackley, C. D., J. K. Yamamoto, N. Levy, N. C. Pedersen, and M. D. Cooper.
1990. Immunologic abnormalities in pathogen-free cats experimentally in-
fected with feline immunodeficiency virus. J. Virol. 64:5652–5655.
2. Alexander, S., and J. H. Elder. 1984. Carbohydrate dramatically influences
immune reactivity of antisera to viral glycoprotein antigens. Science 226:
1328–1330.
3. Baldinotti, F., D. Matteucci, P. Mazzetti, C. Giannelli, P. Bandecchi, F.
Tozzini, and M. Bendinelli. 1994. Serum neutralization of feline immuno-
deficiency virus is markedly dependent on passage history of the virus and
host system. J. Virol. 68:4572–4579.
4. Barlough, J. E., C. D. Ackley, J. W. George, N. Levy, R. Acevedo, P. F. Moore,
B. A. Rideout, M. D. Cooper, and N. C. Pedersen. 1991. Acquired immune
dysfunction in cats with experimentally induced feline immunodeficiency
virus infection: comparison of short-term and long-term infections. J. Ac-
quired Immune Defic. Syndr. 4:219–227.
5. Bosch, M. L., A. C. Andeweg, R. Schipper, and M. Kenter. 1994. Insertion of
N-linked glycosylation sites in the variable regions of the human immuno-
deficiency virus type 1 surface glycoprotein through AAT triplet reiteration.
J. Virol. 68:7566–7569.
6. Davis, D., D. M. Stephens, C. Willers, and P. J. Lachmann. 1990. Glycosy-
lation governs the binding of antipeptide antibodies to regions of hypervari-
able amino acid sequence within recombinant gp120 of human immunode-
ficiency virus type 1. J. Gen. Virol. 71:2889–2898.
7. De Ronde, A., J. G. Stam, P. Boers, H. Langedijk, R. Meloen, W. Hesselink,
L. C. E. J. M. Keldermans, A. van Vliet, E. J. Verschoor, M. C. Horzinek, and
H. F. Egberink. 1994. Antibody response in cats to the envelope proteins of
feline immunodeficiency virus: identification of an immunodominant neu-
tralization domain. Virology 198:257–264.
8. Dow, S. W., M. L. Poss, and E. A. Hoover. 1990. Feline immunodeficiency
virus: a neurotropic lentivirus. J. Acquired Immune Defic. Syndr. 3:658–668.
9. Haigwood, N. L., P. L. Nara, E. Brooks, G. A. Van Nest, G. Ott, K. W.
Higgins, N. Dunlop, C. J. Scandella, J. W. Eichberg, and K. S. Steimer. 1992.
Native but not denatured recombinant human immunodeficiency virus type
1 gp120 generates broad-spectrum neutralizing antibodies in baboons. J.
Virol. 66:172–182.
10. Hansen, J.-E. S., H. Clausen, C. Nielsen, L. S. Teglbjærg, L. L. Hansen,
C. M. Nielsen, E. Dabelsteen, L. Mathiesen, S.-I. Hakomori, and J. O.
Nielsen. 1990. Inhibition of human immunodeficiency virus (HIV) infection
in vitro by anticarbohydrate monoclonal antibodies: peripheral glycosylation
of HIV envelope glycoprotein gp120 may be a target for virus neutralization.
J. Virol. 64:2833–2840.
11. Hoffmann-Fezer, G., J. Thum, C. Ackley, M. Herbold, J. Mysliwietz, S.
Thefeld, K. Hartmann, and W. Kraft. 1992. Decline in CD41 cell numbers
in cats with naturally acquired feline immunodeficiency virus infection. J.
Virol. 66:1484–1488.
12. Hurtrel, M., J.-P. Ganie`re, J.-F. Guelfi, L. Chakrabarti, M.-A. Maire, F.
Gray, L. Montagnier, and B. Hurtrel. 1992. Comparison of early and late
feline immunodeficiency virus encephalopathies. AIDS 6:399–406.
13. Klasse, P. J., J. A. McKeating, M. Schutten, M. S. Reitz, Jr., and M.
Robert-Guroff. 1993. An immune-selected point mutation in the transmem-
brane protein of human immunodeficiency virus type 1 (HXB2-Env:Ala 582
(3 Thr)) decreases viral neutralization by monoclonal antibodies to the
CD4-binding site. Virology 192:332–337.
14. Levy, J. A. 1993. Pathogenesis of human immunodeficiency virus infection.
Microbiol. Rev. 57:183–289.
15. Lombardi, S., C. Garcelli, C. LaRosa, L. Zaccaro, S. Specter, G. Malvaldi, F.
Tozzini, F. Esposito, and M. Bendinelli. 1993. Identification of a linear
neutralization site within the third variable region of feline immunodefi-
ciency virus envelope. J. Virol. 67:4742–4749.
16. McKeating, J. A., J. Gow, J. Goudsmit, L. H. Pearl, C. Mulder, and R. A.
Weiss. 1989. Characterization of HIV-1 neutralization escape mutants.
AIDS 3:777–784.
17. Pancino, G., I. Fossati, C. Chappey, S. Castelot, B. Hurtrel, A. Moraillon, D.
Klatzman, and P. Sonigo. 1993. Structure and variations of feline immuno-
deficiency virus envelope glycoproteins. Virology 192:659–662.
18. Pedersen, N. C., E. W. Ho, M. L. Brown, and J. K. Yamamoto. 1987. Isolation
of a T-lymphotropic virus from domestic cats with an immunodeficiency-like
syndrome. Science 235:790–793.
19. Shelton, G. H., M. L. Linenberger, C. K. Grant, and J. L. Abkowitz. 1990.
Hematologic manifestations of feline immunodeficiency virus infection.
Blood 76:1104–1109.
20. Siebelink, K. H. J., M. L. Bosch, G. F. Rimmelzwaan, R. H. Meloen, and
A. D. M. E. Osterhaus. 1995. Two different mutations in the envelope
protein of feline immunodeficiency virus allow the virus to escape from
neutralization by feline serum antibodies. Vet. Immunol. Immunopathol.
46:51–59.
21. Siebelink, K. H. J., I. Chu, G. F. Rimmelzwaan, K. Weijer, A. D. M. E.
Osterhaus, and M. L. Bosch. 1992. Isolation and partial characterization of
infectious molecular clones of feline immunodeficiency virus obtained di-
rectly from bone marrow DNA of a naturally infected cat. J. Virol. 66:1091–
1097.
22. Siebelink, K. H. J., I. Chu, G. F. Rimmelzwaan, K. Weijer, R. van Herwijnen,
P. Knell, H. F. Egberink, M. L. Bosch, and A. D. M. E. Osterhaus. 1990.
Feline immunodeficiency virus (FIV) infection in the cat as a model for HIV
infection in man: FIV-induced impairment of immune function. AIDS Res.
Hum. Retroviruses 6:1373–1378.
5126 NOTES J. VIROL.
23. Siebelink, K. H. J., G. F. Rimmelzwaan, M. L. Bosch, R. H. Meloen, and
A. D. M. E. Osterhaus. 1993. A single amino acid substitution in hypervari-
able region 5 of the envelope protein of feline immunodeficiency virus allows
escape from virus neutralization. J. Virol. 67:2202–2208.
24. Sodora, D. L., E. G. Sphaer, B. E. Kitchell, S. W. Dow, E. A. Hoover, and J. I.
Mullins. 1994. Identification of three feline immunodeficiency virus (FIV)
env gene subtypes and comparison of the FIV and human immunodeficiency
virus type 1 evolutionary patterns. J. Virol. 68:2230–2238.
25. Sparger, E. E., P. A. Luciw, J. H. Elder, J. K. Yamamoto, L. J. Lowenstine,
and N. C. Pedersen. 1989. Feline immunodeficiency virus is a lentivirus
associated with an AIDS-like disease in cats. AIDS 3:S42–S49.
26. Tozzini, F., D. Matteucci, P. Bandecchi, F. Baldinotti, K. Siebelink, A.
Osterhaus, and M. Bendinelli. 1993. Neutralizing antibodies in cats infected
with feline immunodeficiency virus. J. Clin. Microbiol. 31:1626–1629.
27. Wilson, C., M. S. Reitz, Jr., K. Aldrich, P. J. Klasse, J. Blomberg, R. C.
Gallo, and M. Robert-Guroff. 1990. The site of an immune-selected point
mutation in the transmembrane protein of human immunodeficiency virus
type 1 does not constitute the neutralization epitope. J. Virol. 64:3240–3248.
28. Yamamoto, J. K., E. Sparger, E. W. Ho, P. R. Andersen, T. P. O’Connor,
C. P. Mandell, L. Lowenstine, R. Munn, and N. C. Pedersen. 1988. Patho-
genesis of experimentally induced feline immunodeficiency virus infection in
cats. Am. J. Vet. Res. 49:1246–1258.
VOL. 69, 1995 NOTES 5127
